Cargando…

Astragaloside IV inhibits oxidized low-density lipoprotein-induced endothelial damage via upregulation of miR-140-3p

Mostrar otras versiones (1)

Oxidized low-density lipoprotein (ox-LDL)-mediated endothelial cell injury has an important role in the vascular complications of type 2 diabetes. Astragaloside IV (ASV) is an active component of Radix Astragali, which has been demonstrated to exert protective effects against endothelial damage. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Weibin, Qian, Qiuhai, Cai, Xinrui, Han, Ru, Yang, Wenjun, Zhang, Xinyue, Zhao, Hongmin, Zhu, Ranran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657972/ https://www.ncbi.nlm.nih.gov/pubmed/31257467 http://dx.doi.org/10.3892/ijmm.2019.4257

Ejemplares similares

Astragaloside IV inhibits oxidized low-density lipoprotein-induced endothelial damage via upregulation of miR-140-3p
por: Qian, Weibin, et al.
Publicado: (2023)

Astragaloside IV protects endothelial progenitor cells from the damage of ox-LDL via the LOX-1/NLRP3 inflammasome pathway
por: Qian, Weibin, et al.
Publicado: (2019)

Astragaloside IV modulates TGF‐β1‐dependent epithelial‐mesenchymal transition in bleomycin‐induced pulmonary fibrosis
por: Qian, Weibin, et al.
Publicado: (2018)

Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition
por: Qian, Weibin, et al.
Publicado: (2020)

Astragaloside IV Improves the Barrier Damage in Diabetic Glomerular Endothelial Cells Stimulated by High Glucose and High Insulin
por: Zhao, Tingting, et al.
Publicado: (2022)

Astragaloside IV Protects Against Oxidized Low-Density Lipoprotein (ox-LDL)-Induced Endothelial Cell Injury by Reducing Oxidative Stress and Inflammation
por: Zhu, Zhongsheng, et al.
Publicado: (2019)

Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis
por: Qian, Weibin, et al.
Publicado: (2021)

Metastasis‐associated protein 1 promotes epithelial‐mesenchymal transition in idiopathic pulmonary fibrosis by up‐regulating Snail expression
por: Qian, Weibin, et al.
Publicado: (2020)

Angelica Sinensis Polysaccharide Suppresses Epithelial-Mesenchymal Transition and Pulmonary Fibrosis via a DANCR/AUF-1/FOXO3 Regulatory Axis
por: Qian, Weibin, et al.
Publicado: (2020)

Correction to: Gingerol inhibits cisplatin-induced acute and delayed emesis in rats and minks by regulating the central and peripheral 5-HT, SP, and DA systems
por: Tian, Li, et al.
Publicado: (2020)

Gingerol inhibits cisplatin-induced acute and delayed emesis in rats and minks by regulating the central and peripheral 5-HT, SP, and DA systems
por: Tian, Li, et al.
Publicado: (2019)

Research progress on the mechanism of astragaloside IV in the treatment of asthma
por: Yuan, Fanyi, et al.
Publicado: (2023)

Anticancer effects and mechanisms of astragaloside-IV
por: Zhou, Liangxing, et al.
Publicado: (2022)

Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer
por: Zhang, Wei, et al.
Publicado: (2018)

Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer
por: Zhang, Wei, et al.
Publicado: (2022)

Effects of Astragaloside IV on heart failure in rats
por: Zhao, Zhuanyou, et al.
Publicado: (2009)

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
por: Liu, Wei, et al.
Publicado: (2019)

Astragaloside IV, as a potential anticancer agent
por: Xia, Dongqin, et al.
Publicado: (2023)

Pharmacological Effects of Astragaloside IV: A Review
por: Liang, Yutong, et al.
Publicado: (2023)

Molecular Mechanism of Astragaloside IV in Improving Endothelial Dysfunction of Cardiovascular Diseases Mediated by Oxidative Stress
por: Meng, Peipei, et al.
Publicado: (2021)

Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
por: Qin, Lu-Yun, et al.
Publicado: (2022)

Astragaloside IV improves renal function and alleviates renal damage and inflammation in rats with chronic glomerulonephritis
por: ZHANG, Dong, et al.
Publicado: (2022)

Accelerated Bone Regeneration by Astragaloside IV through Stimulating the Coupling of Osteogenesis and Angiogenesis
por: Wang, Feng, et al.
Publicado: (2021)

The mechanism of astragaloside IV promoting sciatic nerve regeneration
por: Zhang, Xiaohong, et al.
Publicado: (2013)

Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
por: Tan, Yu-Qing, et al.
Publicado: (2020)

Molecular mechanisms of astragaloside-IV in cancer therapy (Review)
por: Chen, Tianqi, et al.
Publicado: (2021)

Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging
por: Zaman, Qumar, et al.
Publicado: (2022)

Astragaloside IV Inhibits Bleomycin-Induced Ferroptosis in Human Umbilical Vein Endothelial Cells by Mediating LPC
por: Sheng, Shuai, et al.
Publicado: (2021)

Astragaloside IV prevents endothelial dysfunction by improving oxidative stress in streptozotocin-induced diabetic mouse aortas
por: Zhang, Yang, et al.
Publicado: (2021)

lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial–mesenchymal transition by competitively binding miR-141-3p
por: Qian, Weibin, et al.
Publicado: (2019)

Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism
por: Zhang, Zhen, et al.
Publicado: (2019)

Protective Effect of Astragaloside IV against Cadmium-Induced Damage on Mouse Renal Podocytes (MPC5)
por: Gong, Pin, et al.
Publicado: (2023)

Astragaloside IV ameliorates renal injury in db/db mice
por: Sun, Huili, et al.
Publicado: (2016)

Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease
por: Xia, Mei-Ling, et al.
Publicado: (2020)

Evaluation of astragaloside IV in hepatic fibrosis: A meta-analysis
por: Han, Zhongying, et al.
Publicado: (2021)

Astragaloside IV alleviates heart failure by modulating Nrf-2
por: Feng, Wenxiao, et al.
Publicado: (2022)

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats
por: Sun, Sen, et al.
Publicado: (2022)

Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases
por: Tan, Junlan, et al.
Publicado: (2023)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases
por: Yang, Chunkun, et al.
Publicado: (2023)

Astragaloside IV protects rat retinal capillary endothelial cells against high glucose-induced oxidative injury
por: Qiao, Yuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9su2mse9q4934sgfgvjsolgr9f